Clovis Oncology (CLVS) Q1 2019 Earnings Call Transcript
CLVS earnings call for the period ending March 31, 2019.
Clovis Oncology
CLVS
CLVS
$17.35
-$0.06
-0.3%
BATS BZX Real Time Price as of May 22, 2019, 3:37 p.m.
View Interactive CLVS Charts
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets.
News & Analysis: Clovis Oncology
The Fool has written over 100 articles on Clovis Oncology.
All
Market Moves
Podcasts
Earnings
Here's Why Clovis Oncology Stock Dropped as Much as 13% Today
The company decided to discontinue an important clinical trial.
Here's Why Clovis Oncology Stock Jumped on Wednesday
Better-than-expected Rubraca sales were just what investors wanted to see.
Clovis Oncology Inc (CLVS) Q4 2018 Earnings Conference Call Transcript
CLVS earnings call for the period ending December 31, 2018.
3 Biotech Stocks That Soared This Week: Are They Buys?
These biotech stocks jumped 31% or more over the last few days. Can their momentum continue?
Here's Why Clovis Oncology Rose as Much as 21.9% Today
The down-on-its-luck pharma company turned in a solid year of growth. Will it be enough to remain competitive -- or find a suitor?
3 Biotechs Gilead Sciences Could Buy in March
With a new CEO from Roche on the way, these companies' odds of being acquired just rose a notch.
Could These Be the Next 2 Biotech Buyouts?
If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
Why GlaxoSmithKline, Clovis Oncology, and Tesaro Are on the Move Today
GlaxoSmithKline's first major pharma acquisition in years isn't a hit with shareholders.
Here's Why Clovis Oncology Stock Dropped a Whopping 60.4% in October
Three separate unfavorable events sent investors packing. Were things really that bad?
